Eric Dobmeier has served as a member of our board of directors since September 2016. Eric is currently President and Chief Executive Officer of Chinook Therapeutics, a private biotechnology company focused on developing novel therapies for kidney disease. He was previously President and Chief Executive Officer of Silverback Therapeutics, and prior to that was Chief Operating Officer of Seattle Genetics, overseeing business development, corporate communications, manufacturing and program/alliance management activities, as well as corporate strategy initiatives. While at Seattle Genetics, Eric was directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Eric also serves on the board of directors of Atara Biotherapeutics, Inc., a publicly-traded biotechnology company. He holds a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University.